Close
Virginia Kaklamani, MD, DSc
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Virginia Kaklamani, MD, DSc
Virginia Kaklamani, MD, DSc, is a professor of medicine in the Division of Hematology-Medical Oncology at The University of Texas Health Science Center San Antonio and is the leader of the breast cancer program at the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center.
She completed her medical training with honors at the University of Athens and her residency in internal medicine at Newton-Wellesley Hospital in Boston. She completed her fellowship in hematology-oncology at Northwestern University. She also received a Master of Science in Clinical Investigation from Northwestern University. She was head of the Translational Breast Cancer Program at Northwestern University and co-director of the cancer genetics program at the same institution.
She has also served as the associate director for clinical research at UT Health San Antonio. Her research interests include designing clinical trials with targeted agents. She has also identified several genetic mutations that link obesity and breast cancer. She is co-director the San Antonio Breast Cancer Symposium, the world's largest breast cancer research symposium.
She was named one of San Antonio’s Top Doctors for Women and San Antonio’s Top Doctors 2021.
Gender
- Female
Languages Spoken
- English
- Greek
Virginia Kaklamani | Breast Oncology
Breast Cancer is a disease we all need to fight together
-
Credentials
Credentials
Positions
- Professor of Medicine, University of Texas Health Science Center San Antonio
- Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
- A.B. Alexander Distinguished Chair in Oncology
- Leader, Breast Cancer Program, UT Health San Antonio MD Anderson Cancer Center
- Co-Director, Cancer Genetics Program, UT Health San Antonio MD Anderson Cancer Center
- Co-Director, San Antonio Breast Cancer Symposium
Certifications
- American Board of Internal Medicine, Hematology Oncology
Education
- Medical School: National & Kapodistrian University of Athens, Athens, Greece
- Residency: Athens Medical School, Athens, Greece
- Doctorate: Doctor of Medical Sciences, National & Kapodistrian University of Athens, Athens, Greece
- Graduate School: Clinical Investigation, Northwestern University, Chicago, IL
-
Locations & Contact
Locations & Contact
Dr. Kaklamani is very, very knowledgeable, very polite. She makes you feel comfortable in the office talking about difficult topics. I would highly recommend her and appreciate her greatly. Thank you.
Patient
-
Research & Publications
Research & Publications
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, García Sáenz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cortés J, Liu S,
BRCA 1/2 gene mutation and gastrointestinal stromal tumours: a potential association
Waisbren J., Uthe R., Siziopikou K., Kaklamani V.
BMJ Case Rep. 2015 Jul 6;2015. pii: bcr2014208830. doi: 10.1136/bcr-2014-208830. PubMed PMID: 26150619.
National comprehensive cancer network. Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.
Daly M.B., Pilarski R., Axilbund J.E., Buys S.S., Crawford B., Friedman S., Garber J.E., Horton C., Kaklamani V., Klein C., Kohlmann W., Kurian A., Litton J., Madlensky L., Marcom P.K., Merajver S.D., Offit K., Pal T., Pasche B., Reiser G., Shannon K.M.,
J Natl Compr Canc Netw. 2014 Sep;12(9):1326-38. PubMed PMID: 25190698
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)
Kaklamani V.G., Jeruss J.S., Hughes E., Siziopikou K., Timms K.M., Gutin A., Abkevich V., Sangale Z., Solimeno C., Brown K.L., Jones J., Hartman A.R., Meservey C., Jovanovic B., Helenowski I., Khan S.A., Bethke K., Hansen N., Uthe R., Giordano S., Rosen S
Breast Cancer Res Treat. 2015 Jun;151(3):629-38. doi: 10.1007/s10549-015-3435-y. Epub 2015 May 26. PubMed PMID: 26006067.
View All Publications — Virginia Kaklamani
-
Clinical Trials
Clinical Trials
Type of Cancer
Breast
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Virginia Kaklamani, MD, DSc
Patient data acquisition and analysis approaches maximizing search for biomarkers considering clinical diagnostic diversity and genetic and epigenetic influence (CTMS# 22-0069)
This is a translational clinical study aiming to develop approaches to process effectively human tissues and identify biomarkers for painful and non-painful chemotherapy-induced peripheral neuropathy (CIPN). This study will involve obtaining two skin biopsies representing affected and non-affected parts of each patient’s limb. Painful and non-painful neuropathies will be determined by a variety…
Type of Cancer
Breast
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Virginia Kaklamani, MD, DSc
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk
A Study of imlunestrant vs physician’s choice endocrine therapy as adjuvant treatment after 2 to 5 years of standard adjuvant endocrine therapy for patients with ER+, HER2- early breast cancer with an increased risk of recurrence
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Virginia Kaklamani, MD, DSc
A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous
This is a Phase 2, randomized, active-controlled, parallel-group, multisite, open-label studyof belzutifan plus fulvestrant versus everolimus plus ETPC (fulvestrant or exemestane) inparticipants with ER+/HER2- unresectable, locally advanced, or mBC.
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Virginia Kaklamani, MD, DSc
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
This is a Phase 3, global, multicenter, randomized, open-label study.
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Virginia Kaklamani, MD, DSc
A Phase 1a/1b Study of the PI3a:RSS Breaker BBO-10203 in Subjects with Advanced Solid Tumors (The BREAKER-101 Trial)
First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with trastuzumab in patients with advanced solid tumors.